Physician profile
Augusto C Posadas, SR.
NPI 1841276961
$14,842.11
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,569 · 2020: $2,793 · 2021: $134 · 2022: $6,346.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,691.15 | 2019-2022 | |
| Genzyme Corporation | $2,733.00 | 2020 | |
| Glaxosmithkline, LLC. | $331.81 | 2019-2022 | |
| Ucb, INC. | $32.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.82 | 2021 | |
| Pfizer INC. | $25.44 | 2020-2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Posadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.